Amgen has announced plans to invest more than $600 million in a new, state-of-the-art centre for science and innovation at its global headquarters in Thousand Oaks, California, US.
The centre is designed to bring together researchers, engineers and scientists across disciplines to enhance collaboration and accelerate the discovery of next-generation therapeutics for patients with the most serious diseases. The building will feature advanced automation and digital capabilities, empowering scientists with the tools and environment needed to drive scientific excellence and advancements in biotechnology.
Amgen's long-standing commitment to US innovation and state-of-the-art operations is reflected in more than $40 billion invested in manufacturing and research and development since the passage of the Tax Cuts and Jobs Act (TCJA) of 2017.
This investment includes over $5 billion in direct capital expenditures in the US. The enactment of pro-growth tax policies in TCJA, extended and reinforced by the One Big Beautiful Bill Act of 2025, further facilitates Amgen's ability to invest domestically in cutting-edge science and manufacturing.
The new centre for science and innovation enhances the company's global network of sites, leveraging decades of operational expertise and technological advancements. Construction is expected to begin in Q3 2025 and create hundreds of US jobs. Amgen has been headquartered in Thousand Oaks, California, part of the greater Los Angeles region, since the company's founding more than 45 years ago.
The announcement builds on other recent investments from the company including a $900 million expansion of its manufacturing facility in Central Ohio and a $1 billion investment to build a second manufacturing plant in Holly Springs, North Carolina.
